Budipine

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Budipine
Budipine.svg
Clinical data
AHFS/Drugs.com International Drug Names
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard 100.055.494 Edit this at Wikidata
Chemical and physical data
Formula C21H27N
Molar mass 293.446 g/mol
3D model (JSmol)
  (verify)

Budipine (brand name Parkinsan) is an antiparkinson agent marketed for the treatment of Parkinson's disease.[2][3][1]

While its exact mechanism of action is not well characterized,[2] it is believed to be an NMDA receptor antagonist,[4][5] but also promoting the synthesis of dopamine.[6]

Because it provides additional benefits relative to existing treatments, it probably does not precisely mimic the mechanism of an existing known treatment.[6][7]

See also[edit]

References[edit]

  1. ^ Martndale: The Complete Drug Reference, 35th Ed.
  2. ^ a b Heinz Reichmann (October 2006). "Budipine in Parkinson's tremor". Journal of the Neurological Sciences. 248 (1-2): 53–55. doi:10.1016/j.jns.2006.05.039. PMID 16784759. 
  3. ^ H. Przuntek; T. Müller (1999). "Clinical efficacy of budipine in Parkinson's disease". Journal of Neural Transmission. Supplementa. 56: 75–82. doi:10.1007/978-3-7091-6360-3_3. PMID 10370903. 
  4. ^ J. Kornhuber, B. Herr, J. Thome, P. Riederer. "The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue". J.Neural Transm.Suppl. 46:127-133, 1995. PMID 8821048
  5. ^ Gene C. Palmer (September 2001). "Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies". Current Drug Targets. 2 (3): 241–271. doi:10.2174/1389450013348335. PMID 11554551. 
  6. ^ a b Przuntek H, Bittkau S, Bliesath H, et al. (May 2002). "Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen". Arch. Neurol. 59 (5): 803–6. doi:10.1001/archneur.59.5.803. PMID 12020263. 
  7. ^ Jenny C.E. Owen; Peter S. Whitton (October 2006). "Effects of amantadine and budipine on antidepressant drug-evoked changes in extracellular dopamine in the frontal cortex of freely moving rats". Brain Research. 1117 (1): 206–212. doi:10.1016/j.brainres.2006.07.039. PMID 16996043.